Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,798 papers from all fields of science
Search
Sign In
Create Free Account
PF 04217903
Known as:
MET Tyrosine Kinase Inhibitor PF-04217903
, PF-04217903
, PF04217903
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Peptide-Functionalized Nanoinhibitor Restrains Brain Tumor Growth by Abrogating Mesenchymal-Epithelial Transition Factor (MET) Signaling.
Yingwei Wu
,
Qi Fan
,
+10 authors
Xiaofeng Tao
Nano letters (Print)
2018
Corpus ID: 51894814
Malignant gliomas are the most common primary brain tumors and are associated with aggressive growth, high morbidity, and…
Expand
Highly Cited
2015
Highly Cited
2015
Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors
I. Yeh
,
T. Botton
,
+11 authors
B. Bastian
Nature Communications
2015
Corpus ID: 17032824
Oncogenic gene fusions have been identified in many cancers and many serve as biomarkers or targets for therapy. Here we identify…
Expand
2013
2013
Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling.
B. Winiarski
,
K. Wolanska
,
+4 authors
J. Whatmore
Translational Oncology
2013
Corpus ID: 24910841
Epithelial ovarian cancer (EOC) metastasizes transcoelomically to the peritoneum and omentum, and despite surgery and…
Expand
Highly Cited
2013
Highly Cited
2013
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.
B. Sennino
,
T. Ishiguro-Oonuma
,
Brian J Schriver
,
J. Christensen
,
D. McDonald
Cancer Research
2013
Corpus ID: 16071307
Inhibition of VEGF signaling can promote lymph node metastasis in preclinical models, but the mechanism is not fully understood…
Expand
Highly Cited
2012
Highly Cited
2012
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.
B. Sennino
,
T. Ishiguro-Oonuma
,
+9 authors
D. McDonald
Cancer Discovery
2012
Corpus ID: 6429102
UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the…
Expand
Highly Cited
2012
Highly Cited
2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6…
J. Cui
,
M. McTigue
,
+20 authors
J. Christensen
Journal of Medicinal Chemistry
2012
Corpus ID: 11238841
The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor…
Expand
Highly Cited
2012
Highly Cited
2012
Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
H. Zou
,
Qiuhua Li
,
+13 authors
J. Christensen
Molecular Cancer Therapeutics
2012
Corpus ID: 207628055
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion, and…
Expand
2012
2012
A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation
N. Lee
,
Maruja Lira
,
+9 authors
K. Ching
PLoS ONE
2012
Corpus ID: 31279252
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit…
Expand
Highly Cited
2011
Highly Cited
2011
Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model
S. Yamazaki
,
J. Skaptason
,
+5 authors
T. Koudriakova
Drug Metabolism And Disposition
2011
Corpus ID: 8218005
The objective of this study was to assess the physiologically based pharmacokinetic (PBPK) model for predicting plasma…
Expand
Highly Cited
2009
Highly Cited
2009
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Sergei L Timofeevski
,
M. McTigue
,
+8 authors
B. Murray
Biochemistry
2009
Corpus ID: 39699975
The c-Met receptor tyrosine kinase (RTK) is a key regulator in cancer, in part, through oncogenic mutations. Eight clinically…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE